DELCATH SYSTEMS, INC Forward looking Statements This presentation contains forward looking statements within the meaning of the Safe Harbor Provisions of the U.S. Private Securities Litigation Reform Act of 1995. These s

Chir Gastroenterol 2003;19:370 376. 2) Curley SA et al. Ann Surg Oncol 1994;1:389 99. 3) Ravikumar TS et al. J Clin Oncol 1994;12:2723 36. 4) Hwu WJ et al. Oncol Res 1999;11:529 37. No. of pts No. of PHP/ pt Disease stage (tumor diameter) Treatment Median survival (mo) Response Rates Reference HCC (n=79) CHM (n=23) 1 4 1 2 IV A: n=66 IV B: n=13 All multiple bilobar Extrahepatic disease in 52% Doxorubicin 60 150 mg/m 2 Cisplatin 50 150 mg/m 2 Mitomycin C 50 200 mg/m 2 16 13 HCC pts RR 64.5% 5 year survival 20.3% Kobe 1 Phase I/II HCC (n=11) 1 3 Mean 9.5 cm Doxorubicin 60 120 mg/m 2 6.5 13 (responders) 2 (non responders) RR 20% MDACC 2 Phase I HCC (n=5) CHM (n=8) Other (n=8) 2 4 Extrahepatic disease in 17% Doxorubicin 50 120 mg/m 2 5 FU 1000 5000 mg/m 2 NR RR 22% Yale 3 Phase I HCC (n=7) Other (n=11) 1 10 NR Doxorubicin 90 120 mg/m 2 23 (responders) 8 (non responders) RR 58% Yale 4 Phase I 47 DELCATH SYSTEMS, INC Appendix V Product Development Pipeline Product Development Pipeline Melanoma liver mets Proprietary drug melphalan CHEMOSAT All liver cancers melphalan Class III medical device 3 rd party melphalan Gen 2 melphalan CE Mark CHEMOSAT for additional drugs CHEMOSAT for other organs (lung and brain) mCRC and HCC indications Initial Opportunity Near Term ( 5 years) Intermediate Term ( 5 years) Doxorubicin system CE Mark mCRC and HCC clinical trials CHEMOSAT for additional drugs CHEMOSAT for other organs (lung and brain) CHEMOSAT Melphalan in South Korea, Japan CHEMOSAT Doxorubicin in China and Taiwan 3 rd party doxorubicin CHEMOSAT for additional drugs CHEMOSAT for other organs (lung and brain) CHEMOSAT Melphalan in Australia and Hong Kong 3 rd party melphalan Development Aligned to Address Significant Market Opportunity 48 DELCATH SYSTEMS, INC E U A S I A U S 2 DELCATH SYSTEMS, INC 2011 DELCATH SYSTEMS, INC.

Ann Oncol. 2010;21:1662 7. Phase II NCI Trial mCRC Cohort 44 DELCATH SYSTEMS, INC Appendix IV Published Phase I/II Studies of Doxorubicin with PHP (percutaneous hepatic perfusion) for HCC 45 DELCATH SYSTEMS, INC CHEMOSAT Doxorubicin Development Multiple published Phase I/II studies from MD Anderson Cancer Center and Yale with percutaneous hepatic perfusion (PHP) and Kobe University using doxorubicin show promising response rates for HCC* Status: o First pass removal efficiency 95% in initial in vitro studies o Utilize new trade secret manufacturing process o Intend to file and seek CE Mark approval in 2H 2012 o Plan to use CHEMOSAT Doxorubicin in Asia Phase III 2L HCC trials Expected Benefits: o Multiple treatments o Reduced systemic toxicity for improved safety profile o Concomitant therapy (complements systemic therapies) Addressing the Large HCC Market Opportunity in China 46 DELCATH SYSTEMS, INC Phase I/II Studies of PHP Doxorubicin For HCC Delivered Safely in Multiple Studies with Promising Response Rates 1) Ku Y et al.

Korea (Device) Japan (Device) Taiwan (Device) Australia (Device) Total Potential (patients) Potential Market ($MM) 1,2 Total Potential Market #Patients HCC (Primary) 85,780 3,258 8,296 2,152 263 99,749 $ 1,156 Other CRC 31,127 3,245 14,298 1,441 2,031 52,143 $ 642 NET 29,197 1,048 2,759 500 462 33,966 $ 393 Ocular Melanoma 1,765 66 175 31 96 2,134 $ 25 Cutaneous Melanoma 382 43 136 246 1,144 1,951 $ 23 OTHER TOTAL 62,472 4,403 17,368 2,218 3,733 90,194 $ 1,083 TOTAL 148,104 7,661 25,665 4,370 3,996 189,943 $ 2,239 APAC Target Markets Represent Over $2 Billion Potential Market Opportunity Sources: LEK Consulting, GLOBOCAN, Company estimates. 1) Assume 2.5 treatments per patient. 2) Estimated ASP of ~$5K. 39 DELCATH SYSTEMS, INC Appendix III CHEMOSAT Melphalan Phase I and II 40 DELCATH SYSTEMS, INC Melphalan Dosing Background Well understood, dose dependant, tumor preferential, alkylating cytotoxic agent that demonstrates little to no hepatic toxicity Manageable systemic toxicities associated with Neutropenia and Thrombocytopenia Drug dosing 12x higher than FDA approved dose via systemic IV chemotherapy Dose delivered to tumor is over 100x higher than that of systemic IV chemotherapy Type Dosing (mg/kg) Multiple Myeloma (label) 0.25 Chemoembolization 0.62 Surgical Isolated Hepatic Perfusion (IHP) 1.50 Myeloablation 2.50 3.50 Chemosaturation (PHP) 3.00 An Established Drug for Liver Cancer Therapy 41 DELCATH SYSTEMS, INC Phase II NCI Trial Metastatic Neuroendocrine Cohort Pre CS (Baseline) Post CS #2 (+4 Months) Post CS #1 (+6 Weeks) Compelling Clinical Data in Attractive mNET Market Phase II mNET Tumor Cohort (n=24)* Number (n) Primary Tumor Histology Carcinoid 4 Pancreatic Islet Cell 20 Response Not Evaluable (Toxicity, Incomplete Treatment, Orthotopic Liver Transplantation) 4 Progressive Disease 2 Minor Response / Stable Disease 4 Partial Response (30.0% 99.0% Tumor Reduction) 13 Complete Response (No Evidence of Disease) 1 Objective Tumor Response 14 Objective Tumor Response Rate 70% Duration (months) Median Hepatic PFS 15.5 Overall Survival After CS 30.4 Presentation at ECCO/ESMO 2011 annual meeting. 42 DELCATH SYSTEMS, INC Phase II NCI Trial HCC Cohort Hepatocellular carcinoma (HCC) is the most common primary cancer of the liver, with approximately 749,000 new cases diagnosed worldwide annually Nine patients with tumors of hepatobiliary origin: five HCC patients and four cholangiocarcinoma patients Both groups received CHEMOSAT procedures and had positive efficacy signals The responses were especially encouraging in the HCC group and consisted of confirmed partial response or durable stable disease Safety profile expected and consistent with pivotal US Phase III melanoma trial Intend to invest in new HCC trials with CHEMOSAT Encouraging Initial Positive Signal for Primary Liver Cancer *Source: GLOBOCAN 43 DELCATH SYSTEMS, INC Substantial clinical evidence of benefit of using melphalan to treat mCRC via isolated hepatic perfusion (IHP) procedure o Over 800 patients treated in 15 studies since 1998 o Patients treated only once o Median response rate of 47% (range 29% 76%) 1 Delcath Phase II NCI Chemosaturation Trial mCRC Cohort o Challenges enrolling at NCI o 16 patients treated since 2004 o Inconclusive efficacy due to advanced disease status (generally 5 th or 6 th line) o Safety profile expected and consistent with pivotal FDA Phase III melanoma trial Intend to invest in new mCRC trials with CHEMOSAT Melphalan Strong Rationale for Using CHEMOSAT with Melphalan to Treat mCRC 1) van Iersel LB, Koopman M, Van D, V, et al.

Chris Houchins SVP, Clinical and Medical Affairs Arno, Schering Plough, Pfizer, Pharmacia, GD Searle 21 Bill Appling SVP Medical Device R D AngioDynamics 26 Dan Johnston, Ph.D. VP, Pharmaceutical R D Pfizer, Wyeth 11 31 DELCATH SYSTEMS, INC Appendices 32 DELCATH SYSTEMS, INC Appendix I Intellectual Property 33 DELCATH SYSTEMS, INC Intellectual Property Patent Protection o 7 issued U.S. patents, 10 foreign patents issued and 4 pending o Primary device patent set to expire August 2016 o Up to 5 years of patent extension post FDA approval Trade Secret Protection o Developed improved filter media via new manufacturing processes FDA Protection o Orphan Drug Designation granted for melphalan in the treatment of ocular melanoma, cutaneous melanoma and metastatic neuroendocrine tumors, as well as for doxorubicin in the treatment of HCC Provides 7 years of marketing exclusivity post FDA approval o Additional Orphan Drug applications to be filed for other drugs and indications, including melphalan for HCC and CRC Multiple Levels of Protection 34 DELCATH SYSTEMS, INC Appendix II CHEMOSAT Market Opportunity by Disease and Target Counties 35 DELCATH SYSTEMS, INC Europe Largest near term opportunity CRC Largest opportunity worldwide Melanoma Largest opportunity is in US China Largest opportunity for HCC Market Opportunity defined as Total Potential Market (TPM) for CHEMOSAT 1.Primary cancer incidence 2.Adjusted for predominant disease in the liver (primary or metastatic cancer) 3.Adjusted for addressable patients via Delcath CHEMOSAT Market Opportunity by Disease (patients) 36 DELCATH SYSTEMS, INC Europe Market by Disease Device Only Germany (Direct) UK (Direct) France (Indirect) Italy (Indirect) Spain (Indirect) Netherlands (Direct) Ireland (Direct) Total Potential (patients) Potential Market ($ MM) 1,2,3 Total Potential Market #Patients Ocular Melanoma 404 297 295 285 197 79 19 1,576 $ 62 Cutaneous Melanoma 1,625 994 753 801 360 379 73 4,987 $ 206 CRC 9,902 5,300 5,475 7,281 4,016 1,644 335 33,953 $1,339 HCC (Primary) 1,637 720 1,514 2,597 1,087 82 35 7,671 $277 NET 1,783 1,336 1,353 1,299 974 360 98 7,202 $ 281 TOTAL 15,351 8,647 9,389 12,263 6,634 2,545 560 55,389 $ 2,166 Europe Presents Significant Potential Market Opportunity Sources: LEK Consulting, GLOBOCAN, Company estimates. 1) Assumes 2.5 treatments per patient. 2) Assumes ASP of ~$15K USD. 3) Assumes mix of direct sales and distributors. 37 DELCATH SYSTEMS, INC US Market by Disease Device and Drug Combination Liver Metastasis Potential Market # Patients Potential Market # Procedures Potential Market ($MM) 1,2 Ocular Melanoma 1,685 4,213 $ 105 Cutaneous Melanoma 7,023 17,557 $ 439 TOTAL MELANOMA (Initial Expected Label) 8,708 21,770 $ 544 CRC 19,861 49,653 $ 1,241 HCC (Primary) 5,586 13,964 $ 349 NET 8,212 20,530 $ 513 OTHER TOTAL (Potential Label Expansion) 33,659 84,147 $ 2,104 TOTAL 42,367 105,917 $ 2,648 Sources: LEK Consulting, GLOBOCAN, Company estimates. 1) Assume 2.5 treatments per patient. 2) Estimated ASP of $25K. 38 DELCATH SYSTEMS, INC APAC Market by Disease China (Device) S.

CMO and EVP, R D Harvard, MIT(HST), Cornell, UMass 32 Agustin Gago EVP, Global Sales AngioDynamics, E Z EM 30 Jennifer Simpson, Ph.D. EVP, Global Marketing Eli Lilly (ImClone), Johnson Johnson (Ortho Biotech) 22 Peter Graham, J.D. EVP, General Counsel Global Human Resources Bracco, E Z EM 17 David McDonald EVP, Business Development AngioDynamics, RBC Capital Markets 29 John Purpura EVP, Regulatory Affairs Quality Assurance E Z EM, Sanofi Aventis 28 Harold Mapes EVP, Global Operations AngioDynamics, Mallinkrodt 26 J.

Daily Volume (3 mo.) 400,000 1) As of March 31, 2012 fully diluted includes an additional 5.0 million options at $4.96 and 2.7 million warrants at $3.03 30 DELCATH SYSTEMS, INC Team Executive Title Prior Affiliation(s) Years of Experience Eamonn Hobbs President and CEO AngioDynamics, E Z EM 31 Graham Miao, Ph.D. EVP CFO D B, Pagoda Pharma, Schering Plough, Pharmacia, JP Morgan 22 Krishna Kandarpa, M.D., Ph.D.

Sorafenib US registration Global Phase 3 Randomized 2L CHEMOSAT Melphalan vs. BSC for Sorafenib Failure Asia Phase 3 Randomized 2L CHEMOSAT Doxorubicin vs. BSC for Sorafenib Failure o mCRC Global Phase 2 Signal Seeking/Safety 2L CHEMOSAT Melphalan US Registration Global Phase 3 Randomized 2L CHEMOSAT Melphalan vs. Approved Alternatives Establish CHEMOSAT as the Standard of Care (SOC) for Disease Control in the Liver 28 DELCATH SYSTEMS, INC 2012 Milestones First patients have been treated with CHEMOSAT Melphalan in Europe Done Execute contract for MSL services in EU 1Q 2012 (Quintiles was selected to support EU launch of CHEMOSAT) Done Secure agreements with 6 8 leading cancer centers in EU Done Obtain CE Mark for Gen 2 CHEMOSAT Melphalan Done US NDA submission in August 2012 Submission for publications of Phase III data and mNET arm of Phase II data 2H 2012 First patients enrolled in EAP September 2012 Submit and seek approval of CE Mark for CHEMOSAT Doxorubicin 2H 2012 Potential Asia strategic partnership dedicated BD with China a top priority 29 DELCATH SYSTEMS, INC Financial Update Cash Cash Equivalents: $20.8 million at March 31, 2012 Financing Program $4.8 million raised via At The Market (ATM) equity offering program in Q1 2012 Working Capital Line of Credit $20.0 million credit facility Cash Spend: $14.7 million in Q1 2012 Debt: None Shares Outstanding: 49.8 million (57.5 million fully diluted 1 ) Institutional Ownership 22% Market Capitalization $155 million as of March 31, 2012 Avg.

Commercialization Strategy Initial focus on leading cancer centers and referring community hospitals Educate Medical Oncologists via Medical Science Liaison (MSL) Direct strategy to sell to Interventional Radiologists and Surgeons: 12 sales territories ultimately expanding to as many as 60 territories as revenues ramp 5 Clinical Specialists initially to support site initiation and training Utilize top centers from Phase III trial as Centers of Excellence for training and support Intend to seek chemosaturation specific codes based upon value proposition relative to other cancer therapies Direct Sales Channels Supplemented with Contract MSLs 27 DELCATH SYSTEMS, INC Clinical Development Program Goal: o Expand indications for HCC and mCRC with US registration trials o Generate robust clinical data to support commercialization Submitted IND Amendment to include Gen 2 in Expanded Access Program (EAP), compassionate use and all future clinical trials o Assuming IND Amendment accepted, initiate EAP for metastatic melanoma in September 2012 Planned Clinical Trials (first patient enrolled in 2013) o HCC Global Phase 2 randomized 1L CHEMOSAT Melphalan vs.

Korea 2013 Singapore 2013 Brazil 2013 Intend to submit applications Israel Canada Mexico/Argentina Russia India Japan China and Taiwan Utilize 3 rd party melphalan and doxorubicin available to physicians Combination of Strategic Partnerships and Specialty Distributors 25 DELCATH SYSTEMS, INC U.S. FDA Regulatory Status Pre NDA submission meeting with FDA conducted in January 2012 o Satisfied with FDA response o Addressed RTF related issues Manufacturing plant inspection timing Product and sterilization validation Additional statistical analysis clarification Additional safety data Completed data entry and monitoring o Completed data migration to new FDA compliant CDISC database o Created new Case Report Form (CRF) We will lock database on May 25, 2012 Plan to file NDA submission in Mid August 2012 Initiated dialogue with FDA to discuss optimal approval path for Gen 2 Progress on Track to Submit NDA 26 DELCATH SYSTEMS, INC U.S.

Italy) o Apply for funding under existing New Technology Payment programs (e.g. NUB in Germany and HAS in France) o Other oncology therapies currently reimbursed, despite lacking randomized data Reimbursement Mechanisms in Place to Support Commercial Launch 24 DELCATH SYSTEMS, INC International Strategy beyond EU and US Leverage CE Mark to obtain reciprocal regulatory approvals for CHEMOSAT System in other international markets International regulatory submissions status: Application submitted and expected approvals in Australia 2012 (approved) Hong Kong 2012 S.

Pascale in Naples, Italy o Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital o Universidad de Navarra Pamplona, Spain Training completed and first patients treated at IEO and JWG University Hospital, Frankfurt, Germany o Cutaneous melanoma, ocular melanoma, gastric cancer, and breast cancer liver metastases Agreements with additional leading cancer centers expected in Target Countries in 2012 Selected Quintiles to support EU launch We are establishing direct sales force in UK, Germany and Netherlands and seeking exclusive distributors in Italy, France and Spain 23 DELCATH SYSTEMS, INC European Reimbursement Considerations No centralized pan European medical device reimbursement body regional and national systems Devices typically reimbursed under Diagnosis Related Groups (DRG) as part of a procedure Working with reimbursement specialists to develop a plan in each of our key markets Immediate reimbursement plans: o Utilize existing codes where permitted until permanent reimbursement established (e.g.

EU: Initial target countries of Germany, UK, Italy, France, Spain, Netherlands, Ireland. APAC: Initial target countries of China, Japan, S. Korea, Taiwan, Australia. Assumes 2.5 treatments per patient. Assumes EU ASP of $15K; US ASP of $25K; APAC ASP of $5K. 55,389 $2.2 B 8,708* $2.6 B 189,943 $2.2 B HCC CRC Melanoma NET 19 DELCATH SYSTEMS, INC Approved (CE Mark Device) Regulatory Filing (NDA) Planned in August, 2012 Application Submitted/ Planned Mutual Recognition of European CE Mark in 2012 2013 Global Commercialization Status On The Cusp of Addressing A Multi Billion Dollar Global Market in Next Two Years 20 DELCATH SYSTEMS, INC European Commercialization Strategy Strategy: Focus efforts in 7 Target Countries (EU 5 + Netherlands Ireland) 8 10 leading EU cancer centers as initial training centers Validate business model and demonstrate scalability Push and Pull marketing and selling strategy Tactics Execution: Educate medical oncologists via contract organization Sell to hospital based interventional radiologists, surgeons and C suite decision makers with combination of direct sales and distributors Hospitals procure melphalan from third parties and physicians use at their discretion Establish European patient education awareness programs (PR, website) Leverage existing new technology reimbursement channels, while pursuing permanent procedure reimbursement via Health Technology Assessment (HTA) Clinical trials to generate additional data for CRC and HCC to support revenue ramp up Currently In Initial Training and Marketing Phase 21 DELCATH SYSTEMS, INC Patient Referral Path Interventional Radiologist Offers chemosaturation procedure Patient Primary Care Medical Oncologist Offers systemic therapy Surgical Oncologist Offers resection or other focal therapy Chemosaturation Diagnosis of Cancer Identification of liver involvement with no improvement from systemic therapy When liver disease is controlled patients return to the Medical Oncologist for additional systemic therapy 22 DELCATH SYSTEMS, INC CHEMOSAT Training and Marketing Commenced in Europe Continue Training and Marketing Centers Roll Out Entered training and marketing agreements with leading cancer centers in Europe o Institute of European Oncology (IEO), Milan, Italy o Johann Wolfgang Goethe (JWG) University Hospital, Frankfurt, Germany o University Medical Center Schleswig Holstein, Kiel Campus, Germany o Institut Gustave Roussy ( IGR ), Villejuif, France o Instituto Oncologico Baselga (IOB), Grupo Quiron, Barcelona, Spain o Istituto Nazionale Tumori Fondazione G.

ISOLATE 2. SATURATE 3. FILTRATE The Delcath CHEMOSAT System Improved disease control in the liver Treats entire liver (macro and micro) Controls systemic toxicities Allows for over 100x effective dose escalation at tumor site Repeatable minimally invasive, Complements systemic therapy Minimally Invasive, Repeatable Liver Procedure That Could Complement Systemic Therapy Note: Image not to scale. 8 DELCATH SYSTEMS, INC Concentrating the Power of Chemotherapy for Disease Control in the Liver The Data We conducted a randomized Phase 3 study under a Special Protocol Assessment ( SPA ) using Generation 1 of our chemosaturation system in patients with melanoma (ocular and cutaneous) metastatic to the liver Melanoma liver metastases are relatively homogeneous regardless of origin Liver metastases are typically the life limiting aspect of the disease Melanoma is notoriously insensitive to systemic chemotherapy and our study was a great demonstration of our technology s potential in a challenging histology 9 DELCATH SYSTEMS, INC Phase III Clinical Trial Design Randomized to CS 92 patients: ocular or cutaneous melanoma Best Alternative Care (BAC) Investigator and patient decision (any and all treatments) CS/Melphalan Treat every 4 weeks x 4 rounds (responders can receive up to 6 rounds) Cross over Primary Trial Endpoint Statistically significant difference in Hepatic Progression Free Survival ( hPFS ): p 0.05 Over 80% of Oncologic drugs approved by FDA between 2005 2007 on endpoints other than overall survival Modeled hPFS for Trial Success: 7.73 months (CS) vs. 4 months (BAC) Secondary Trial Endpoints Hepatic response and duration of hepatic response Overall response and duration of overall response Overall Survival Diluted by Cross Over SAP calls for analysis of various patient cohorts Pre CS (Baseline) Post CS (22+ Months) Hepatic Response Metastatic Melanoma Fully Powered, 93 Patient, Randomized, Multi Center NCI Led Study CS = ChemoSaturation (CHEMOSAT) 10 DELCATH SYSTEMS, INC Phase 3 Hepatic Progression free Survival (ITT) Hazard Ratio: 0.35 (CI: 0.23 0.54) 0 5 10 15 20 25 30 35 Months CS PHP BAC 8.0 1.6 p 0.0001 1.0 Survival probability 0.8 0.6 0.4 0.2 0.0 CS PHP Demonstrated a 5x Improvement in Primary Endpoint of hPFS 11 DELCATH SYSTEMS, INC Phase 3 Overall Progression free Survival (ITT) Hazard Ratio: 0.36 (CI: 0.23 0.57) 0 5 10 15 20 25 30 35 Months CS PHP BAC 6.7 1.6 p 0.0001 1.0 Survival probability 0.8 0.6 0.4 0.2 0.0 CS also Demonstrated a Highly Statistically Significant Improvement in Overall PFS 12 DELCATH SYSTEMS, INC Overall survival (ITT population) 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 12 36 0 24 48 Time (months) 60 p value = 0.4170 BAC PHP Censored observations BAC vs PHP 55% Cross over HR=1.20 (CI: 0.78 1.85) Overall Survival Confounded By Crossover Study Design 9.8 10.0 13 DELCATH SYSTEMS, INC Overall survival (ITT population) Time (months) 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 12 36 0 24 48 60 4.1 PHP randomized BAC crossover* BAC only* Censored observations PHP randomized vs PHP crossover vs BAC only 9.8 13.1 Overall Survival Tail PHP Treated Patients * Similar patient characteristics and demographics between BAC crossover and BAC only 14 DELCATH SYSTEMS, INC Overall survival (ITT population) 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 12 36 0 24 48 60 11.4 Total PHP incl. crossover BAC only Censored observations Time (months) Total PHP vs BAC only 4.1 Overall Survival Tail For Treated Patients 15 DELCATH SYSTEMS, INC Positive Phase III Results* Primary endpoint exceeded, p value = 0.0001, hazard ratio of .35 o Treatment arm shows 5x median hepatic progression free (hPFS) survival compared to control arm o CS/PHP median hPFS of 8.0 months compared to 1.6 months for BAC o 86% overall clinical benefit (CR + PR + SD) Secondary endpoints support results o OS Secondary endpoint No difference in Kaplan Meier curves due to cross over treatment response (9.8 months compared to 10.0 months) o CS/PHP median overall PFS of 6.7 months vs. 1.6 months for BAC OS exploratory cohort analysis favorable o Median survival of 9.8 months for treatment arm compared to 4.1 months non crossover BAC patients o Median survival of 11.4 months for all patients treated with melphalan, including crossover o 8 CS/PHP treated patients and 2 BAC treated patients still alive as of 4/2012 Gen 1 Safety profile expected and consistent with currently approved labeling for melphalan o 30 day deaths on PHP: 3/44 patients (6.8%) 1 Neutropenic Sepsis (2.3%); 1 Hepatic Failure 2.5% (95% tumor burden); 1 gastric perforation o 30 day deaths on BAC: 3/49 patients (6.1%) Trial Outcomes Favorable and Consistent with Special Protocol Assessment * Updated Investigator results presented at 2011 ECCO/ESMO Annual Meeting. 16 DELCATH SYSTEMS, INC Melphalan Sensitivity: In Vitro Tumor Cell Lines Study Cancer Origin (Cell lines) Apoptosis Induction (uM) Thyroid 2.54 Ovarian 4.31 Melanoma 4.53 CNS 6.40 Sarcoma 6.68 Head and Neck 6.78 Bladder 9.50 Colon 15.12 Cervix 15.16 Prostate 17.55 Liver 23.23 Pancreas 25.00 Lung 28.60 Breast 31.82 Kidney 35.30 Uterus 44.60 We Believe CHEMOSAT Will Be Effective On a Wide Variety of Histologies Melphalan Sensitivity Apoptosis Induction Melphalan Conc. achieved during CHEMOSAT = ~ 192 uM Tissue of Origin for Cell Line 17 DELCATH SYSTEMS, INC Our Opportunity At the concentrations of melphalan we are achieving in the liver, we believe CHEMOSAT will be effective on a wide variety of histologies We believe that physicians are recognizing the broad applicability of CHEMOSAT, based on early experience and their interest in testing our technology with melphalan in a variety of tumor histologies CE Mark approved broad indication Large global market opportunity with pharmaceutical like gross margin Concentrating the Power of Chemotherapy for Disease Control in the Liver 18 DELCATH SYSTEMS, INC CHEMOSAT Potential Multi Billion Dollar Market 8,708 6,563 4,085 8,212 7,202 33,966 19,861 33,953 52,143 5,585 7,671 99,749 0 25,000 50,000 75,000 100,000 125,000 150,000 175,000 200,000 USA EU APAC $7 Billion Annual Global Opportunity with Pharmaceutical Like Gross Margins Sources: LEK Consulting, GLOBOCAN, Company estimates. *TPM for initial U.S. labeled indication only.

These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission including our annual report on Form 10 K and our reports on Forms 10 Q and 8 K. You should not place undue reliance on these forward looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward looking statements to reflect events or circumstances after the date they are made. 3 DELCATH SYSTEMS, INC Our Mission Concentrating the Power of Chemotherapy for Disease Control in the Liver We are a cancer therapy company Our technology offers the opportunity to gain control of tumors in the liver The liver is a site where uncontrolled disease is often life limiting or leads to withdrawal of systemic treatments in favor of palliative care We plan on being a fully integrated company and are building the infrastructure to develop and commercialize our products in Europe and North America o In Europe our first product is approved and we have begun selling it We believe that our first product, CHEMOSAT, may extend the lives of a large number of cancer patients 4 DELCATH SYSTEMS, INC Existing Liver Cancer Treatments Have Significant Limitations The Problem Metastatic disease to the liver, brain or lungs is often the life limiting location of solid tumors o In contrast to the brain and lungs, where systemic chemotherapy and radiation can exert some degree of local control, tumors in the liver are not particularly responsive to chemotherapy and radiation therapy Existing treatments to control tumors in the liver include: Surgical resection Radioembolization (SIRT) Chemoembolization (TACE) Radiofrequency ablation (RFA), Microwave, Cryoablation Hepatic arterial infusion (HAI) Systemic chemotherapy 5 DELCATH SYSTEMS, INC Existing Liver Cancer Treatments Have Limitations Unmet Medical Need Exists for More Effective Liver Cancer Treatments Treatment Advantages Disadvantages Systemic Non invasive Repeatable Systemic toxicities Limited efficacy in liver Regional (e.g., Isolated Hepatic Perfusion) Therapeutic effect Targeted Invasive/limited repeatability Multiple treatments are required but not possible Focal (e.g. surgery, radioembolization, chemoembolization, radio frequency ablation) Partial removal or treatment of tumors Only 10% to 20% resectable Invasive and/or limited repeatability Treatment is limited by tumor size, number of lesions and location See a tumor, treat a tumor 6 DELCATH SYSTEMS, INC Concentrating the Power of Chemotherapy for Disease Control in the Liver Our Solution Our proprietary CHEMOSAT system isolates the liver circulation, delivers an ultra high concentration of chemotherapy (melphalan) to the liver and filters most of the chemotherapy out of the blood prior to returning it to the patient The procedure typically takes approximately two hours to complete and involves a team including the interventional radiologist and perfusionist CHEMOSAT (Gen 2) has demonstrated minimal systemic toxicities and impact to blood components in initial commercial use and may complement systemic therapy CHEMOSAT has been used on approximately 200 patients to date through clinical development and early commercial launch 7 DELCATH SYSTEMS, INC Chemosaturation 1.

Factors that may cause such differences include, but are not limited to, uncertainties relating to: the benefits of the Gen 2 CHEMOSAT system and market acceptance of the same, patient outcomes using the Gen 2 CHEMOSAT system, agreements with additional early launch centers in Europe, our ability to manufacture CHEMOSAT systems and the time required to build inventory and establish commercial operations in Europe, adoption, use and resulting sales, if any, for the CHEMOSAT system in the EEA, our ability to successfully commercialize the chemosaturation system and the potential of the chemosaturation system as a treatment for patients with cancers in the liver, acceptability of the Phase III clinical trial data by the FDA, our ability to address the issues raised in the Refusal to File letter received from the FDA and the timing of our re submission of our NDA, re submission and acceptance of the Company's NDA by the FDA, approval of the Company's NDA for the treatment of metastatic melanoma to the liver, adoption, use and resulting sales, if any, in the United States, approval of the CHEMOSAT system in foreign markets, approval of the current or future chemosaturation system for other indications and/or with other chemotherapeutic agents, actions by the FDA or other foreign regulatory agencies, our ability to obtain reimbursement for the CHEMOSAT system, our ability to successfully enter into distribution and strategic partnership agreements in foreign markets and the corresponding revenue associated with such foreign markets, uncertainties relating to the timing and results of research and development projects and future clinical trials, acceptance of our IND amendment, submission and publication of the Phase II and III clinical trial data, the timing and use, if any, of the line of credit from SVB and our ability to access this facility, and uncertainties regarding our ability to raise additional capital and obtain financial and other resources for any research, development and commercialization activities.

Investor Presentation (NASDAQ: DCTH) May 2012 Exhibit 99.1 2 DELCATH SYSTEMS, INC Forward looking Statements This presentation contains forward looking statements within the meaning of the Safe Harbor Provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statement are subject to certain risks and uncertainties that can cause actual results to differ materially from those described.